ArticleLab on a chip2019
A microfluidic patterned model of non-alcoholic fatty liver disease: applications to disease progression and zonation.
Article in Lab on a chip, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Article
- Metabolic dysfunction-associated steatotic liver disease and steatohepatitis-associated hepatocarcinoma preclinical models.Nature reviews. Gastroenterology & hepatology · 2026Review
- Primary Human Tissue Models for Metabolic Dysfunction-Associated Liver Disease - toward Streamlining Drug Discovery with Patient-Derived Assays.Advanced biology · 2025Review
- In vitro liver models for toxicological research.Drug metabolism and pharmacokinetics · 2025Review
- Transcriptomic and Proteomics Analysis of a Lipid-Loaded HepaRG Model for Steatosis Reveals Altered Regulation in Lipid and Xenobiotic Metabolism.Current drug metabolism · 2025Article
- Microfluidic Flow Promotes a Steatotic Phenotype in Induced Pluripotent Stem Cell-Derived Hepatocytes that is Influenced by Disease State of the Donor.Gastro hep advances · 2025Review
- Ex Vivo Tools and Models in MASLD Research.Cells · 2024Review
- Microfluidic 3D hepatic cultures integrated with a droplet-based bioanalysis unit.Biosensors & bioelectronics · 2024Article
- Microfluidic design for in-vitro liver zonation-a numerical analysis using COMSOL Multiphysics.Medical & biological engineering & computing · 2024Article
- A comprehensive review on 3D tissue models: Biofabrication technologies and preclinical applications.Biomaterials · 2024Review
- Opportunities and considerations for studying liver disease with microphysiological systems on a chip.Lab on a chip · 2023Review
- Characterisation of hepatic lipid signature distributed across the liver zonation using mass spectrometry imaging.JHEP reports : innovation in hepatology · 2023Article
- A Microfluidic Device for Long-Term Maintenance of Organotypic Liver Cultures.Advanced materials technologies · 2023Article
- Liver Regeneration and Immunity: A Tale to Tell.International journal of molecular sciences · 2023Review
- State-of-the-art liver disease research using liver-on-a-chip.Inflammation and regeneration · 2022Review
- Liver-on-a-chip: Considerations, advances, and beyond.Biomicrofluidics · 2022Review
- Microfluidic Organ-on-a-Chip Devices for Liver Disease Modeling In Vitro.Micromachines · 2022Review
- Studying metabolism with multi-organ chips: new tools for disease modelling, pharmacokinetics and pharmacodynamics.Open biology · 2022Review
- Microtechnology-basedAPL bioengineering · 2021Review
- Hepatocyte cultures: From collagen gel sandwiches to microfluidic devices with integrated biosensors.APL bioengineering · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Non-alcoholic fatty liver disease (NAFLD) and its progressive form non-alcoholic steatohepatitis (NASH) affect 25% of the world population. NAFLD is predicted to soon become the main cause of liver morbidity and transplantation. The disease is characterized by a progressive increase of lipid accumulation in hepatocytes, which eventually induce fibrosis and inflammation, and can ultimately cause cirrhosis and hepatic carcinoma. Here, we created a patterned model of NAFLD on a chip using free fatty acid gradients to recapitulate a spectrum of disease conditions in a single continuous liver tissue. We established the NAFLD progression via quantification of intracellular lipid accumulation and transcriptional levels of fatty acid transporters and NAFLD pathogenesis markers. We then used this platform to create oxygen driven steatosis zonation mimicking the sinusoidal lipid distribution on a single continuous tissue and showed that this fat zonation disappears under progressed steatosis, in agreement with in vivo observations and recent computational studies. While we focus on free fatty acids and oxygen as the drivers of NAFLD, the microfluidic platform here is extensible to simultaneous use of other drivers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.